SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

TScan Therapeutics cut to Neutral from Buy by HC Wainwright

HC Wainwright & Co. downgraded TScan Therapeutics to Neutral from Buy, according to Benzinga ratings actions cited by TradingView News.

TCRX
SquawkNews Desk

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories

VICI Properties Closes $500 Million Term Loan to Refinance 2027 Notes VICI Properties said a subsidiary closed a $500 million term loan to refinance 2027 notes. M impact | EQUITY | Nov 12, 2026, 10:32 PM UTC Flowers Foods Cuts Full-Year Outlook After Third-Quarter Results Flowers Foods said consumer spending weakness and increased promotional activity weighed on third-quarter results. It reported profit of $14.4 million, or 7 cents a share; the outl M impact | EQUITY | Nov 12, 2026, 10:31 PM UTC Dropbox Plans $1 Billion Convertible Notes Offering Dropbox plans a $1 billion private offering of convertible senior notes. M impact | EQUITY | Nov 12, 2026, 10:31 PM UTC MediaAlpha Repurchases $16 Million in Stock From White Mountains Affiliate MediaAlpha said it repurchased 1.13 million shares from an affiliate of White Mountains Insurance Group at $14.15 per share, about a 5.5% discount to Wednesday’s closing price. L impact | EQUITY | Nov 12, 2026, 10:29 PM UTC Cerebras CFO Expects Flat Q4 Sequential Cloud Revenue on Capacity Limits Cerebras Systems’ CFO expects cloud revenue to be flat sequentially in Q4, limited entirely by data center capacity. M impact | EQUITY | Nov 12, 2026, 10:28 PM UTC Nscale Expects $21 Billion to $22 Billion in Monarch Campus Capex Nscale expects capital expenditure of about $21 billion to $22 billion for GPUs and other compute equipment at Monarch Compute Campus under an Anthropic services agreement. M impact | EQUITY | Nov 12, 2026, 10:27 PM UTC